News‎ > ‎News Feed‎ > ‎

Liraglutide for adolescent obesity: study suggests safe and tolerable

posted 24 Jan 2017, 14:03 by Damian Wood
A study by Danne et al and supported by Novo Nordisk A/S published in the Journal of Pediatrics appears to show that Liraglutide, a treatment for adult obesity, is safe and tolerable in adolescents and shows a similar pharmacokinetic profile to adults. Abdominal pain was the main adverse effect.  The SCALE study showed that high dose (3mg) once daily subcutaneous Liraglutide was associated with around 6kgs of weight loss over a year when used alongside diet and exercise intervention for weight management in adult participants.. 

The study is available as Open Access: